Heart failure & cardiomyopathiesSecondary analysis
Effect of Paced Heart Rate on Quality of Life and Natriuretic Peptides for Stage B or C Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of the myPACE Trial
- Secondary analysis of the myPACE randomised trial
- post-hoc analysis
- ANCOVA design
Authors' conclusion
In the post-hoc analysis of the myPACE trial, we observed that the benefits of a personalized accelerated backup pacing on MLHFQ score, NT-proBNP, and pacemaker-detected activity levels appear to be more pronounced in patients with smaller iLVEDV and higher LVEF.
Study context
- Population
- Heart failure with preserved ejection fraction (HFpEF) patients with preexisting pacemakers and pre-trial transthoracic echocardiograms
- Participants
- 93 patients
- Comparison
- Personalized accelerated pacing vs usual care, by left ventricular (LV) volumes and LV ejection fraction (LVEF)
- myPACEn = 44
- Usual caren = 49reference
- Primary endpoint
- Changes in MLHFQ score, NT-proBNP, pacemaker-detected activity levels and AF burden across LV volumes and LVEF
Primary result
As reported in the abstract
N-terminal pro-brain natriuretic peptide (NT-proBNP) improved more with myPACE at lower indexed LV end-diastolic volumes (iLVEDV)
interaction p = 0.006
Minnesota Living with Heart Failure Questionnaire (MLHFQ) improved more with myPACE at lower iLVEDV
interaction p = 0.068
Activity levels improved more with myPACE at higher LVEF
interaction p = 0.009
NT-proBNP improved more with myPACE at higher LVEF
interaction p = 0.058
Original publication
Summarised from the published abstract; every number is checked against it